Zurita SG, Briones CMC, Preciado RV, Uraga PR

Language: Spanish
References: 22
Page: 205-209
PDF size: 740.13 Kb.

ABSTRACT

One of the considered highly efficient treatments against vitiligo is narrow band UV-B phototherapy, but their adverse effects limit its use. On the other hand, Polypodium leucotomos with photoimmunoprotection and antioxidant actions decrease the phototoxicity of the ultraviolet radiation. The objective of this study is to determine if P. leucotomos: blocks or increase the therapeutic effect of the UV-B narrow band. This is a double blind clinical study that involves patients with vitiligo which UV-B narrow band phototherapy has been prescribed. Thirteen patients with vitiligo were enrolled to the study. The mean of age was 27 ± 12. The mean of the number of spots was 8 ± 6. The mean of the evolution time was 8 ± 10 months. From the thirteen patients, five patients (38%) dropped out the research and 8 (62%) finished it. From the 8 patients who finished the study, 4 received P. leucotomos (grup A) and 4 received placebo (grup B). The group A started with a mean of depigmentation area of 35 ± 21%, and finished with a mean of depigmentation of 16 ± 17%. The group B started with a depigmentation mean of 26 ± 13% and finished with 6 ± 4%. We believe that we could employ the P. leucotomos, combined with any ultraviolet therapy due to its therapeutic effects are not affected, and it adds the benefit to diminish the phototoxicity, specially in vitiligo because P. leucotomos would contribute with its immunomodulating actions.

REFERENCES

1. Westerhof W, Nieuweboer-Krobotova L. Treatment of Vitiligo with UVB radiation vs Topical Psoraleno Plus UV-A. Arch Dermatol 1997; 133: 1591-2.

2. Njoo MD, Spuis Pl, Boss JD, Westerhof W, Bussuyt Pm. Nonsurgical repigmentation teherapies in vitiligo. Meta-anàlisis of the literature. Arch Dermatol 1998; 134: 1532-40.

3. Roelandts R. Photo(chemo) therapy for vitiligo. Photodermatol Photoinmmunol Photomed 2003; 19: 1-4.

4. Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow- band UVB for the treatment of vitiligo: an emerging effective and welltolerated therapy. Int J Dermatol 2005; 44: 57-60.

5. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow band (TL01) UVB radiation therapy. J Am Acad Dermatol 2000; 4: 1-12.

6. Lepe V, Moncada Benjamín, Castanedo- Cazares JP, Torres-Alvarez MB, Ortiz C, Torres- Rubalcava A. A doule-blind randomized trial of 0.1% Tacroloimus vs 0.005% clobetasol for the tratment of chilhood vitiligo. Arch Dermatol 2003; 139: 581-4.

7. Fai D, Cassano N, Vena GA. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. JEADV 2007; 21: 916-20.

8. Zurita G, Galán R, Ochoa E, Uraga E. Pimecrolimus asociado a fototerapia UVB de banda estrecha (311 nm) en vitíligo. Med Cutan Iber Lat Am 2005; 33: 103-7.

9. Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153: 498-505.

10. Ogawa Y, Adachi A, Tomita Y. The successful use of topical tacrolimus treatment for a chronic actinic dermatitis patient with complications of idiopathic leukopenia. J Dermatol 2003; 30: 805-9.

11. Mayuzumi N, Ikeda S, Kawada H, Ogawa H. Effects of drugs and anticytokine antibodies on expression of ATP2A2 and ATP2C1 in cultured normal human keratinocytes. Br J Dermatol 2005; 152: 920-4.

12. Lan CC, Yu HS, Wu CS. Kuo Hy, Chai CY, Chen GS. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factorkappaB. Br J Dermatol 2005; 153: 725-32.

13. Brieva A, Alonso-Lebrero JL, Tejedor R. Antiinflamatory activity of the hidrophilic extract of Polypodium leucotomos. 20th World Congress of Dermatology (Abstract).

14. Siscovick JR, Zapolanski T, Magro C, Carrington K, Prograis S, Nussbaum M et al. Polypodium leucotomos inhibits ultraviolet B radiationinduced immunosuppression. Photodermatol Photoimmunol Photomed 2008; 24: 134-41.

15. Zattra E, Coleman C, Arad S, Helms E, Levine D, Bord E, et al. Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol 2009; 175: 1952- 61.

16. Brieva A, Panizo G, Tejedor R, Guerrero A, Alonso-Lebrero JL. Characterization of antioxidant activity of Polypodium leucotomos extract. 20th World Congress of Dermatology (Abstract).

17. Brieva A, Panizo G, Tejedor R, Guerrero A, Alonso-Lebrero JL. Characterization of photoprotective activity of Polypodium leucotomos extract. 20th World Congress of Dermatology (Abstract).

18. Middelkamp-Hup MA, Pathak M, Rius Díaz F, Fitspatrick TB, González S. First systemic oral agent that inhibits PUVA- induced phototoxicity of human skin. 20th World Congress of Dermatology (Abstract).

19. Azmi M. Vitiligo repigmentation with anopsos polipodium leucotomos. 1989 Int J Dermatol 28: 479.

20. Middelkamp-Hup MA, Bos JD, Rius-Díaz F, González S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2007; 21: 942-50.

21. DA Shephard. The 1975 Declaration of Helsinki and consent. Can Med Assoc J 1976; 115: 1191-2.

22. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. T cells in psoriatic lesional skin that survive conventional therapy with NBUVB radiation display reduced IFN-gamma expression. Arch Dermatol Res 2004; 295: 509-16.